Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

por Lissitchkov, Toshko, Willemze, Annemieke, Jan, Christelle, Zilberstein, Moshe, Katragadda, Suresh
Publicado 2023

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study

por Lissitchkov, Toshko, Willemze, Annemieke, Katragadda, Suresh, Rice, Kara, Poloskey, Stacey, Benson, Craig
Publicado 2022

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophi...

por Shah, Anita, Solms, Alexander, Garmann, Dirk, Katterle, Yvonne, Avramova, Verzhiniya, Simeonov, Stanislav, Lissitchkov, Toshko
Publicado 2016

octanate(®): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

por Klukowska, Anna, Komrska, Vladimír, Vdovin, Vladimír, Zozulya, Nadezhda, Lissitchkov, Toshko, Oldenburg, Johannes, Ettingshausen, Carmen Escuriola
Publicado 2020

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients

por Pabinger, Ingrid, Lissitchkov, Toshko, Nagao, Asuza, Lepatan, Lynda Mae, Li, Yanyan, Seifert, Wilfried, Mancuso, Maria Elisa
Publicado 2023

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

por Windyga, Jerzy, Stasyshyn, Oleksandra, Lissitchkov, Toshko, Mamonov, Vasily, Serban, Margit, Rusen, Luminita, Ploder, Bettina, Tangada, Srilatha
Publicado 2020

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Wille...

por Lissitchkov, Toshko, Klukowska, Anna, Buevich, Evgeny, Maltceva, Irina, Auerswald, Guenter, Stasyshyn, Oleksandra, Seifert, Wilfried, Rogosch, Tobias
Publicado 2020

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

por Pulanić, Dražen, Bátorová, Angelika, Bodó, Imre, Červinek, Libor, Ionita, Ioana, Lissitchkov, Toshko, Melikyan, Anahit, Podolak-Dawidziak, Maria
Publicado 2023

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-...

por Lissitchkov, Toshko J., Buevich, Evgeny, Kuliczkowski, Kazimierz, Stasyshyn, Oleksandra, Cerqueira, Monica Hermida, Klukowska, Anna, Joch, Christine, Seifert, Wilfried
Publicado 2017

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

por Mancuso, Maria Elisa, Lubetsky, Aaron, Pan‐Petesch, Brigitte, Lissitchkov, Toshko, Nagao, Azusa, Seifert, Wilfried, Li, Yanyan, Santagostino, Elena
Publicado 2020

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

por Shah, Anita, Solms, Alexander, Wiegmann, Sara, Ahsman, Maurice, Berntorp, Erik, Tiede, Andreas, Iorio, Alfonso, Mancuso, Maria Elisa, Zhivkov, Tihomir, Lissitchkov, Toshko
Publicado 2019

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

por Solms, Alexander, Shah, Anita, Berntorp, Erik, Tiede, Andreas, Iorio, Alfonso, Linardi, Camila, Ahsman, Maurice, Mancuso, Maria Elisa, Zhivkov, Tihomir, Lissitchkov, Toshko
Publicado 2020

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B

por Windyga, Jerzy, Timofeeva, Margarita, Stasyshyn, Oleksandra, Mamonov, Vasily, Lamas Castellanos, José Luis, Lissitchkov, Toshko, Chojnowski, Krzysztof, Chapman, Miranda, Pavlova, Borislava G., Tangada, Srilatha
Publicado 2020

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

por Lissitchkov, Toshko, Klukowska, Anna, Pasi, John, Kessler, Craig M., Klamroth, Robert, Liesner, Raina J., Belyanskaya, Larisa, Walter, Olaf, Knaub, Sigurd, Bichler, Johann, Jansen, Martina, Oldenburg, Johannes
Publicado 2019

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

por Pasi, K. John, Lissitchkov, Toshko, Mamonov, Vasily, Mant, Tim, Timofeeva, Margarita, Bagot, Catherine, Chowdary, Pratima, Georgiev, Pencho, Gercheva‐Kyuchukova, Liana, Madigan, Kate, Van Nguyen, Huy, Yu, Qifeng, Mei, Baisong, Benson, Craig C., Ragni, Margaret V.
Publicado 2021

Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients

por Lissitchkov, Toshko, Madan, Bella, Djambas Khayat, Claudia, Zozulya, Nadezhda, Ross, Cecil, Karimi, Mehran, Kavakli, Kaan, De Angulo, Guillermo R., Almomen, Abdulkareem, Subramanian, Kannan, D'Souza, Fulton, Viswabandya, Auro, Hoorfar, Hamid, Schwartz, Bruce A., Solomon, Cristina, Knaub, Sigurd, Peyvandi, Flora
Publicado 2020